ENTPD1 and pulmonary emphysema: We show that the expression of CD39 in lung tissue in patients with COPD (in the initial phase) is diminished; therefore, as found in the animal model of Lazar et al. [17], administering a CD39 analogue might protect against the development of pulmonary emphysema and inflammation in human patients as well.